Amarantus Bioscience Holdings, Inc. has announced it has formed a wholly-owned subsidiary named Elto Pharma, Inc. for the purpose of further development of Eltoprazine, a mid-stage central nervous system (CNS) symptomatic treatment for Adult Attention Deficit and Hyperactivity Disorder (Adult ADHD), Alzheimer's Aggression and Parkinson's disease Levodopa-induced Dyskinesia (PD-LID).
Concurrently, Amarantus has formed the wholly-owned subsidiary MANF Therapeutics, Inc. for continued pre-clinical development of the MANF program in development for the treatment of ophthalmological disorders, including the orphan indications retinitis pigmentosa (RP) and retinal artery occlusion (RAO), in addition to Glaucoma and Parkinson's disease.
Eltoprazine has completed Phase 2 clinical studies in Adult ADHD, Alzheimer's Aggression and PD-LID. MANF has completed safety and efficacy animal proof of concept studies in RP, RAO, Glaucoma and Parkinson's disease.